默沙东阿瑞匹坦是什么药？

It is a neurokinin-1 (NK-1) receptor blocker developed by Merck, which can inhibit the vomiting induced by cytotoxic chemotherapy drugs, such as cisplatin, through its central effect. It can penetrate the blood-brain barrier and occupy substance P neurokinin 1 receptors in the brain, thereby inhibiting vomiting.

Merck is a company located in Kenilworth, New Jersey, USA, with approximately 70,000 employees worldwide (as of December 31, 2014). In 2014, Merck's global sales totaled US$42.2 billion, and its R&D investment reached US$6.5 billion.

What kind of medicine is MSD aprepitant?

Merck is used in combination with other anti-emetic drugs to prevent acute or delayed nausea and vomiting that occurs during initial or repeated chemotherapy for highly or moderately emetic tumors. The drug blocks the effects of substance P by binding to NK-1 receptors (mainly found in the central nervous system and its periphery), and can pass through the blood-brain barrier and occupy NK-1 receptors in the brain, with selectivity and high affinity, but low affinity for NK-2 and NK-3 receptors. At the same time, its affinity for the targets of other drugs used to treat chemotherapy-induced nausea and vomiting symptoms (such as dopamine receptors and 5-HT receptors) is also very low, and its effect in reducing nausea and vomiting is better than other drugs.

Recommended related hot articles: /newsDetail/96569.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.